Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Gastrointestinal 1

Conditions

Cholangiocarcinoma 5Urinary Bladder Neoplasms 3Acrocephalosyndactylia 3Stomach Neoplasms 2Glioblastoma 2Breast Neoplasms 2Uterine Cervical Neoplasms 1Upper Tract Urothelial Carcinomas 1Tumor With Alterations of the FGF-R 1Squamous Cell Carcinoma of Head and Neck 1Renal Pelvis and Ureter Urothelial Carcinoma 1Rectal Neoplasms 1Papillomavirus Infections 1Pancreatic Neoplasms 1Oncogenic osteomalacia 1Neoplasms 1Neoplasm Metastasis 1Nasopharyngeal Neoplasms 1Melanoma 1Lung Neoplasms 1Liver Neoplasms 1Hypophosphatemia 1Hematologic Neoplasms 1Glioma 1Colonic Neoplasms 1Central Nervous System Neoplasms 1Advanced Gastrointestinal Stromal Tumor (GIST) 1

Interventions

infigratinib 1Imatinib Mesylate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Advanced Gastrointestinal Stromal Tumor (GIST) × infigratinib × Clear all
NCT02257541 2020-03-30

BGJ398 in Combination With Imatinib Mesylate in Patients With Untreated Advanced Gastrointestinal Stromal Tumor (GIST)

Memorial Sloan Kettering Cancer Center

Phase 1/2 Completed
16 enrolled 14 charts
GastrointestinalSarcoma

Advanced Gastrointestinal Stromal Tumor (GIST)

Data powered by HemOnc (CC BY 4.0) Colophon âš¡